Stockreport

ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fra [Read more]